Vanessa Kachadurian Biosciencetechnology MRI abnormality 9 times more likely to get Breast Cancer

Healthy women possessing a certain abnormality on MRIs are nine times more likely to get breast cancer, according to research published in Radiology. The abnormality is called background parenchymal enhancement (BPE), a phenomenon in which areas of normal background breast tissue appear white, or enhanced.
The magnitude of the link was so strong, it could lead to improved cancer detection and therapy, if future research concurs.
“The degree of the impact of BPE on risk for developing breast cancer was surprising,” senior author, and Seattle Cancer Care Alliance Director of Radiology, Constance Lehman, M.D., Ph.D., FACR, told Bioscience Technology. “While we hypothesized BPE would increase a woman’s risk of developing breast cancer, we did not predict over a 9 fold increased risk.”
The impact may go far beyond finding cancer earlier.
http://www.biosciencetechnology.com/articles/2015/05/women-mri-abnormality-nine-times-more-likely-get-breast-cancer

Vanessa Kachadurian Bioscience - New COPD drug clears Phase III

 

Novartis ($NVS), working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.

The two inhaled treatments are NVA237, a bronchodilator marketed as Seebri Breezhaler overseas, and QVA149, which combines the active ingredient in NVA237 with Novartis' approved Onbrez.
In one Phase III program, the twice-daily QVA149 met its goals of significantly improving COPD patients' lung function compared to placebo and its individual components alone. The inhaler also met its secondary goals of improving breathlessness and quality of life, Novartis said. And in two separate late-stage studies, NVA237 beat placebo in improving lung function, meeting its primary endpoint. Both treatments charted a similar profile to placebo and their comparator agents, the company said.
http://www.fiercebiotech.com/story/novartis-duo-copd-drugs-clears-phase-iii-path-fda-decision/2015-05-22

Vanessa Kachadurian Check out my Social Updates on Social Brands Today

http://www.socialbrands.today/social-directory/people/1390-vanessa-Kachadurian

Vanessa Kachadurian illustrates low pressure sales to close the deal

Vanessa Kachadurian Bioscience - Strong Dividend Meridian Bioscience

Shares of Meridian Bioscience (NASDAQ:VIVO) saw unusually-strong trading volume on Friday following a dividend announcement from the company, ARN reports. Approximately 488,537 shares traded hands during trading, an increase of 56% from the previous session’s volume of 313,124 shares.The stock last traded at $17.69 and had previously closed at $17.34.
The newly announced dividend is will be paid on Friday, February 13th. Stockholders of record on Monday, February 2nd will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 4.61%. The ex-dividend date is Thursday, January 29th.
A number of analysts have recently weighed in on VIVO shares. Analysts at Craig Hallum upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating and raised their price target for the stock from $19.00 to $22.00 in a research note on Friday. Analysts at Zacks upgraded shares of Meridian Bioscience from an “underperform” rating to a “neutral” rating and set a $17.00 price target on the stock in a research note on Monday, January 12th. Analysts at Raymond James downgraded shares of Meridian Bioscience from a “market perform” rating to an “underperform” rating in a research note on Friday, January 2nd. Finally, analysts at TheStreet downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Friday, December 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Meridian Bioscience currently has an average rating of “Hold” and an average price target of $20.50.
The stock has a 50-day moving average of $16.67 and a 200-day moving average of $18.17. The company has a market cap of $739.2 million and a price-to-earnings ratio of 20.89.
Meridian Bioscience (NASDAQ:VIVO) last released its earnings data on Thursday, January 22nd. The company reported $0.19 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.19. The company had revenue of $48.00 million for the quarter, compared to the consensus estimate of $46.20 million. Analysts expect that Meridian Bioscience will post $0.86 EPS for the current fiscal year.
Meridian Bioscience, Inc (NASDAQ:VIVO) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Vanessa Kachadurian Teaches Businesses To Sell | Segment News

Vanessa Kachadurian Bioscience

Amgen's ($AMGN) promising cardio drug aced its 6th late-stage study, the company said, beating out statins in patients with a cholesterol-boosting genetic disorder and widening the drugmaker's lead in a potentially lucrative new field.
In its latest Phase III trial, Amgen said evolocumab (AMG 145) met its primary endpoint of significantly lowering LDL cholesterol in 49 patients with homozygous familial hypercholesterolemia, a rare ailment that lifts "bad" cholesterol levels to dangerous highs in adolescents. Evolocumab works by blocking the protein PCSK9 and thus helping the body clear LDL cholesterol from the blood, and Amgen said its latest study was the first to test out the pathway in patients with the disease, which affects about one in a million people.
The top-line success comes on the heels of 5 Phase III wins for evolocumab, and Amgen is working through a total of 14 studies on the drug with eyes on filing an FDA application this year. If everything goes according to plan, the California biotech will be the first PCSK9 player on the market, getting first crack at what could be a $10 billion market and beating out Regeneron ($REGN) and Sanofi's ($SNY) alirocumab and Pfizer's ($PFE) bococizumab (RN-316).

Read more: Amgen goes 6-for-6 in Phase III, leading the race for a new cardio blockbuster - FierceBiotech http://www.fiercebiotech.com/story/amgen-goes-6-6-phase-iii-leading-race-new-cardio-blockbuster/2014-03-17#ixzz2zUb3MJ00
Subscribe at FierceBiotech